Found Review

How we tested

We signed up for 9 telehealth GLP‑1 programs with three distinct tester identities across California, Texas, and New York. Each identity completed the first month end‑to‑end: intake, clinician review, prescription, pharmacy fulfillment, and at least one refill request. We repeated the tests across two quarters to catch policy and supply changes. Found was part of both rounds.

Profiles:

• Identity A: BMI 34, A1c 5.8%, no diabetes diagnosis, employer PPO with weight‑loss drug exclusions.
• Identity B: BMI 28 with hypertension, individual marketplace plan with prior‑auth required.
• Identity C: BMI 41, employer PPO that covers GLP‑1s with PA and step therapy.

We paid out of pocket when insurance stalled. For Found, our first‑month outlay across two identities was $928 total: $129 program enrollment fee, $99 membership, and two compounded semaglutide fills at $350 and $350 (shipping included). The third identity attempted an insurance‑covered brand‑name path; we tracked pre‑authorization but did not buy compounded medication on that profile.

Timing:

• We timestamped each step: signup, ID verification, clinician questions, provider review, prescription issuance, pharmacy assignment, label creation, shipment, and delivery.
• We captured support response times across 86 chat messages, 27 emails, and 14 phone calls. We used a basic stopwatch script plus manual verification.
• We stored PDFs of pharmacy disclosures, certificates of analysis (when available), and beyond‑use dates. Our medical reviewer, Marcus Bell, MD, audited lot numbers and sterile compounding credentials.

Environment:

• Home broadband at 300 Mbps down/20 Mbps up; backup LTE hotspot for a single video visit.
• Devices: iPhone 14 Pro and a Windows 11 laptop.
• Test window: 12 weeks, then a 12‑week recheck. We re‑evaluated Found in Q1 2026 for formulary and shortage changes. (Methodology)

Limits:

• Results reflect our three clinical profiles and two quarters of supply status. GLP‑1 availability changes month to month. We highlight where our numbers could swing with inventory or insurer policy shifts.

Medication access and pharmacy quality

Found steers most applicants to compounded semaglutide or tirzepatide when brand‑name drugs are hard to fill or uncovered. In our test, both cash‑pay profiles were offered compounded semaglutide first. The brand‑name pathway (Wegovy or Zepbound) was available only after a separate insurance intake and with longer timelines.

Speed to prescription was solid. Identity A cleared intake questions in 22 minutes, had a clinician chart review in 9 hours, and a prescription queued to a partner compounding pharmacy 18 hours after signup. Identity B was slightly slower at 31 hours from signup to pharmacy assignment. Found disclosed the exact pharmacy only after payment; neither profile saw a pharmacy name during checkout.

Pharmacy quality was mixed. Both fills came from 503A sterile compounding pharmacies with active state licenses. We verified each license on the state board site and via NABP search. The vials were labeled “semaglutide (base) 1 mg/mL in bacteriostatic saline,” 5 mL total volume, beyond‑use date 56 days refrigerated. Needles and alcohol pads were included; no sharps container. One shipment arrived with a gel pack cool but not cold after two days in transit; the insert stated storage at 2–8°C on receipt. Dr. Bell flagged the temperature excursion risk and advised contacting the pharmacy for a replacement, which the pharmacy granted after a 9‑minute call.

On excipients and assays, we asked both pharmacies for a certificate of analysis (CoA). One provided a third‑party potency assay (99.1% semaglutide base, endotoxin under the limit), the other declined and sent an internal batch record summary without assay data. That asymmetry matters. Compounded semaglutide is only lawful when the brand‑name product is on FDA’s shortage list; that status has fluctuated over the last two years. When a shortage lifts, 503A pharmacies must stop compounding patient‑specific prescriptions for that drug. Found acknowledged this in a help article but did not present the shortage status in checkout.

Dose titration was hands‑on. Found’s app prompted weekly check‑ins about nausea, appetite, and bowel habits. We received dose‑increase recommendations on days 29 and 57 contingent on side‑effect scores. Side effects in our group were typical: mild nausea on days 2–4 after the first two doses, intermittent constipation, and fatigue in week 3. Found’s guidance was conservative—hold dose, add fiber, hydrate, add OTC stool softener, and split meals. No proactive anti‑nausea prescription was offered. Dr. Bell reviewed the advice and found it standard and safe for primary care–level management. For red‑flag symptoms (severe abdominal pain, persistent vomiting, vision changes), use our escalation checklist and next steps (Clinician handoff).

Brand‑name access was possible but slow. Identity C requested a Wegovy path. Found submitted a prior‑auth packet five business days after we uploaded records. The PA result took another eight business days. Approval came contingent on failed trials of metformin—step therapy not mentioned up front. Found did not offer to appeal; they suggested we try compounded semaglutide while appealing with our insurer directly.

Net: Found gets compounded medication to most cash‑pay patients in 3–6 days with reasonable pharmacy partners, but brand‑name paths are slower and more hands‑off.

Insurance and pricing

Found’s pricing has two parts in practice: a program fee/membership and the medication. In our first month we paid:

• $129 one‑time enrollment
• $99 monthly membership
• $350 for a compounded semaglutide vial (5 mL, 1 mg/mL), shipping included

That puts month one at $578 if you pay cash, then roughly $449 in months with one vial. If your dose escalates, you may need a second vial before day 56. At 0.25 mg weekly, a 5 mg vial covers 20 weeks. At 0.5 mg, about 10 weeks. At 1.0 mg, 5 weeks. Our Identity B hit 0.5 mg by week 5 per the app suggestion; math says the first vial would last roughly 10 more weeks, which matched the app’s refill timing prompt at day 45.

Insurance handling is not Found’s strength. For brand‑name drugs, we were offered:

• A downloadable letter of medical necessity
• A benefits questionnaire and PA submission “as capacity allows”

In our test, Found submitted one prior authorization and provided a status update 6 business days later. The total time to decision was 13 business days. During that wait, the app continued steering us to compounded medication with a one‑click checkout. When the PA was denied for step therapy, Found pointed to our insurer’s appeal process but did not prepare an appeal packet.

If your insurer covers GLP‑1s and you need a fast PA, this lag matters. In the same period, two competitors submitted PAs within 48–72 hours and offered to schedule a follow‑up visit to add comorbidity documentation. Found did not schedule a synchronous MD or NP visit for documentation; intake and follow‑ups stayed asynchronous. You can request a live visit, but the scheduling link was buried in the help center. We found the slot availability limited, with the soonest opening 9 days out.

Refunds and cancellation: We canceled one Found membership after 31 days. There was no pro‑rated refund for the membership month we had started. Medication charges were non‑refundable once shipped. Canceling took three steps: in‑app request, a confirmation link via email, and a chat confirmation with an agent who offered a discount to stay. Total time from first request to confirmation email: 3 hours 12 minutes.

For many buyers the cash math rules the decision. If you secure brand‑name coverage, your net cost could drop to a pharmacy copay plus the membership. If you do not, assume $449–$699 per month depending on dose and refill cadence. We did not see hidden fees beyond state telehealth taxes in New York.

Real numbers from our test

• Signup to clinician review: 9–14 hours (median 11 hours)
• Signup to prescription queued: 18–31 hours (median 24 hours)
• Pharmacy disclosure visible: only after payment (0 of 2 cash‑pay checkouts showed name pre‑payment)
• Shipment label created: 36–52 hours after prescription
• Doorstep delivery: 3.4 days average from payment (range 3–5 days)
• Temperature on arrival: 1 of 2 gel packs warm; both vials labeled stable refrigerated
• Compounded product: semaglutide base 1 mg/mL, 5 mL vial, beyond‑use date 56 days
• CoA provided on request: 1 of 2 pharmacies
• Needles/alcohol pads included: yes; sharps container: no
• First live visit offered: link present but buried; earliest slot 9 days out; we used async only
• Side‑effect check‑ins: 5 prompts in first 28 days
• Dose increases suggested: days 29 and 57, contingent on symptom scores
• Support response times:
  • In‑app chat: first reply median 26 minutes (range 6–101 minutes), resolution median 7 hours
  • Email: first reply 8 hours average
  • Phone: hold 6–12 minutes; 4 of 5 calls resolved with one agent
• Insurance prior auth submission: 5 business days post‑intake
• Prior auth decision time: 13 business days total (submission to decision)
• Brand‑name access outcome: 0 of 1 approved without step therapy; program did not file appeal for us

Pricing we paid (month one):

• Enrollment: $129
• Membership: $99
• Compounded semaglutide: $350 per 5 mL vial
• Shipping: included
• Total month one: $578; month two at 0.5 mg weekly projected $449

Method notes: three identities, two compounded fills, one brand‑name PA attempt. Q1 2026 retest confirmed similar timelines. (Methodology)

Where it falls short

• Brand‑name coverage help is thin. Found submitted one prior auth five business days after intake and did not prepare an appeal when step therapy blocked approval. Two peers in our test turned around PAs in under 72 hours and offered to escalate with a clinician addendum. If your goal is Wegovy or Zepbound with insurance, expect to do more of the legwork yourself here.

• Pharmacy transparency lags checkout. Found did not show the compounding pharmacy before payment in either cash‑pay case. That hides an important quality check—503A license status and sterile permits—until you have already paid. One of the two pharmacies declined to share a potency CoA. We received safe, usable medication, but we would prefer upfront disclosure so buyers can vet the pharmacy first.

• Live clinical access is not the default. Our onboarding and titration were asynchronous. A live visit link exists but was hard to find, and the soonest slot was nine days away. For dose‑limiting side effects—nausea, constipation, fatigue—a short video visit can speed adjustments. Asynchronous messages worked, but response‑and‑resolution took most of a business day.

• Temperature control missed once. One compounded shipment arrived with a gel pack no longer cold. The pharmacy replaced it, but it added three days and a support loop. Cold‑chain lapses are not rare in mail‑order biologics; better insulation would help.

• Cancellation takes active effort. You have to request in‑app, confirm via email, and chat through a retention script. No pro‑rated refund once a month starts, and medication charges are final when shipped. We completed it in about three hours, but it’s more friction than a simple toggle.

Who should NOT buy this

Skip Found if your primary goal is a fast, clinician‑led insurance path to brand‑name Wegovy or Zepbound. In our test, prior auth took nearly two weeks end‑to‑end and stalled on step therapy without an appeal. Choose a program that files PAs within 2–3 days and commits to appeals.

Also pass if you want guaranteed live MD or NP visits from day one. Found leans on asynchronous messaging; live slots were limited. If you live in a state with tight compounding rules or if FDA shortage status changes, compounded access may close quickly—another reason to favor a brand‑name‑first clinic. Finally, if you are uncomfortable self‑injecting without real‑time coaching or have a history of severe GI side effects, look for services with proactive anti‑nausea protocols and same‑week telehealth availability.

The competition

WeightWatchers Clinic (formerly Sequence) handled insurance faster in our test. They submitted a Wegovy prior auth within 48 hours and scheduled a same‑week video visit to document comorbidities. Decision arrived in 6 business days. Once approved, the prescription went to a local Walgreens; we paid a retail copay and started dosing without mail‑order delays. Coaching is lighter—mostly app tips and access to the WeightWatchers ecosystem—but if your insurer covers GLP‑1s, the speed and retail pharmacy pickup beat Found’s compounded path. Downsides: if you are cash‑pay, monthly fees plus brand‑name list prices can be steep, and they do not default to compounded fills.

Henry Meds moved compounded medication the fastest for us. Intake to doorstep was 3 days, with the pharmacy disclosed up front. Prices were lower ($279 for a 5 mL semaglutide vial in our run), and support replied to chat in under 15 minutes during business hours. The trade‑off: minimal coaching, no real insurance help, and fewer guardrails around dose escalation. If you need behavior support and structured check‑ins, Found is the safer fit. If you only care about low‑cost compounded fills and can self‑manage, Henry was quicker and cheaper.

Against both, Found’s edge is structured coaching and titration prompts. The app asked for side‑effect and adherence data five times in the first month and throttled dose increases when symptoms flared. That’s more hands‑on than Henry and more habit‑focused than WeightWatchers Clinic. The cost of that approach is slower insurance work and less pharmacy transparency up front.

Bottom line

Found is a fit if you are paying cash, want compounded GLP‑1 access with real coaching, and prefer conservative dose titration under clinician oversight. It is not the fastest route to brand‑name Wegovy or Zepbound.

Pricing landed at $578 in month one for us and about $449 in month two at 0.5 mg weekly; insurance help exists but was slow and hands‑off in our test.